Compare Eli Lilly And Co (LLY) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs SYSCO Corporation — how do they compare? Eli Lilly And Co trades at $1,159.54 (market cap $1.02T), while SYSCO Corporation trades at $81.37 (market cap $38.63B). The key difference: Eli Lilly And Co is far larger — about 26.4× SYSCO Corporation's market cap, and SYSCO Corporation pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| LLY | SYY | |
|---|---|---|
Market Cap | $1.02T | $38.63B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $91.16 |
52-Week Low | $625.65 | $69.30 |
Enterprise Value | $1.06T | $52.11B |
Dividend Yield | 0.6% | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SYY trades at $81.02, down 0.82% on the day, with a neutral technical signal and support at $81. The company reported $81.37B in revenue for 2025 with a net margin of 2.08%, and upcoming Q4 2026 earnings on August 4 are expected at $1.51 EPS. Positive cash flow trends and a dividend of $0.55 payable July 24 provide stability, while analyst consensus is bullish with a $84.75 price target.
Outlook is cautiously optimistic given analyst buy ratings (60%) and steady revenue growth, but risks include thin profit margins and high debt levels. The stock offers value with a P/S of 0.47, though near-term performance hinges on earnings results and macroeconomic conditions affecting the food distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
